Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Donald

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
The Pediatric Infectious Disease Journal|February 9, 2012
A proposed comprehensive classification of tuberculosis disease severity in childrenCatherine A Wiseman, Robert P Gie, Jeffrey R Starke, et al.
The Lancet. Infectious Diseases|September 9, 2010
Tuberculous meningitis: a uniform case definition for use in clinical researchSuzaan Marais, Guy Thwaites, Johan F Schoeman, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosisLizanne de Kock, Sherwin K B Sy, Bernd Rosenkranz, et al.
Annals of Tropical Paediatrics|June 20, 2002
Human immunodeficiency virus infection in children hospitalised with tuberculosisHeleen J Blussé van Oud-Alblas, Margreet E van Vliet, Jan L L Kimpen, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2015
N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosisSherwin K B Sy, Lizanne de Kock, Andreas H Diacon, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2005
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosisFrik A Sirgel, P Bernard Fourie, Peter R Donald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2011
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?Jakko van Ingen, Rob E Aarnoutse, Peter R Donald, et al.
Pediatrics|April 16, 2009
Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South AfricaGijs T J van Well, Berbe F Paes, Caroline B Terwee, et al.
Frontiers in Neurology|April 4, 2022
Tuberculous Meningitis in Children: A Forgotten Public Health EmergencyKaren du Preez, Helen E Jenkins, Peter R Donald, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2012
Phase II dose-ranging trial of the early bactericidal activity of PA-824Andreas H Diacon, Rodney Dawson, Jeannine du Bois, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
The Pediatric Infectious Disease Journal|February 9, 2012
A proposed comprehensive classification of tuberculosis disease severity in childrenCatherine A Wiseman, Robert P Gie, Jeffrey R Starke, et al.
The Lancet. Infectious Diseases|September 9, 2010
Tuberculous meningitis: a uniform case definition for use in clinical researchSuzaan Marais, Guy Thwaites, Johan F Schoeman, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosisLizanne de Kock, Sherwin K B Sy, Bernd Rosenkranz, et al.
Annals of Tropical Paediatrics|June 20, 2002
Human immunodeficiency virus infection in children hospitalised with tuberculosisHeleen J Blussé van Oud-Alblas, Margreet E van Vliet, Jan L L Kimpen, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2015
N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosisSherwin K B Sy, Lizanne de Kock, Andreas H Diacon, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2005
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosisFrik A Sirgel, P Bernard Fourie, Peter R Donald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2011
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?Jakko van Ingen, Rob E Aarnoutse, Peter R Donald, et al.
Pediatrics|April 16, 2009
Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South AfricaGijs T J van Well, Berbe F Paes, Caroline B Terwee, et al.
Frontiers in Neurology|April 4, 2022
Tuberculous Meningitis in Children: A Forgotten Public Health EmergencyKaren du Preez, Helen E Jenkins, Peter R Donald, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2012
Phase II dose-ranging trial of the early bactericidal activity of PA-824Andreas H Diacon, Rodney Dawson, Jeannine du Bois, et al.
Pageof 9